Clinical and genetic predictions of early-onset cardiac toxicity in adjuvant chemotherapy for breast cancer
Aim: To identify clinical and genetic variants associated with early-onset cardiac toxicity with a low cumulative dose of chemotherapy drugs in breast cancer. Methods: A total of 388 recruited patients completed routine blood, liver and kidney function, D-dimer, troponin T, brain natriuretic peptide (BNP) or N-terminal prohormone of BNP, ECG and echocardiography tests before and after adjuvant chemotherapy. 25 single-nucleotide polymorphisms (SNPs) were tested. Results: A total of 277 adjuvant chemotherapy-related cardiac toxicity events were recorded in 180 patients (46.4%). Anthracycline-containing chemotherapy (odds ratio: 1.848; 95% CI: 1.135-3.008; p = 0.014) and the SLC28A3 rs885004 GG genotype (odds ratio: 2.034; 95% CI: 1.189-3.479; p = 0.010) were found to be associated with overall cardiac toxicity. The final predictive risk model consisting of clinical risk factors and SNPs was better than SNP alone (p = 0.006) or clinical risk factor alone (p = 0.065). Conclusion: On the basis of clinical factors, a prediction model with genetic susceptibility factors can better predict early-onset cardiac toxicity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Future oncology (London, England) - 18(2022), 17 vom: 19. Juni, Seite 2127-2139 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Binliang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
114471-18-0 |
|---|
| Anmerkungen: |
Date Completed 04.05.2022 Date Revised 04.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/fon-2021-1021 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339437421 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339437421 | ||
| 003 | DE-627 | ||
| 005 | 20231226002908.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/fon-2021-1021 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1131.xml |
| 035 | |a (DE-627)NLM339437421 | ||
| 035 | |a (NLM)35414207 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Binliang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical and genetic predictions of early-onset cardiac toxicity in adjuvant chemotherapy for breast cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.05.2022 | ||
| 500 | |a Date Revised 04.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: To identify clinical and genetic variants associated with early-onset cardiac toxicity with a low cumulative dose of chemotherapy drugs in breast cancer. Methods: A total of 388 recruited patients completed routine blood, liver and kidney function, D-dimer, troponin T, brain natriuretic peptide (BNP) or N-terminal prohormone of BNP, ECG and echocardiography tests before and after adjuvant chemotherapy. 25 single-nucleotide polymorphisms (SNPs) were tested. Results: A total of 277 adjuvant chemotherapy-related cardiac toxicity events were recorded in 180 patients (46.4%). Anthracycline-containing chemotherapy (odds ratio: 1.848; 95% CI: 1.135-3.008; p = 0.014) and the SLC28A3 rs885004 GG genotype (odds ratio: 2.034; 95% CI: 1.189-3.479; p = 0.010) were found to be associated with overall cardiac toxicity. The final predictive risk model consisting of clinical risk factors and SNPs was better than SNP alone (p = 0.006) or clinical risk factor alone (p = 0.065). Conclusion: On the basis of clinical factors, a prediction model with genetic susceptibility factors can better predict early-onset cardiac toxicity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a early-onset cardiac toxicity | |
| 650 | 4 | |a predictive risk model | |
| 650 | 4 | |a risk factors | |
| 650 | 4 | |a single-nucleotide polymorphisms | |
| 650 | 7 | |a Anthracyclines |2 NLM | |
| 650 | 7 | |a Natriuretic Peptide, Brain |2 NLM | |
| 650 | 7 | |a 114471-18-0 |2 NLM | |
| 700 | 1 | |a Guan, Xiuwen |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yanfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Xiaoying |e verfasserin |4 aut | |
| 700 | 1 | |a Yi, Zongbi |e verfasserin |4 aut | |
| 700 | 1 | |a Lv, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Wenna |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Lixi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhai, Jingtong |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Fei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future oncology (London, England) |d 2005 |g 18(2022), 17 vom: 19. Juni, Seite 2127-2139 |w (DE-627)NLM161450725 |x 1744-8301 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2022 |g number:17 |g day:19 |g month:06 |g pages:2127-2139 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/fon-2021-1021 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2022 |e 17 |b 19 |c 06 |h 2127-2139 | ||